PURPOSE: Accurate breast cancer risk assessment is vital to personalize screening and risk reduction strategies. Women with atypical hyperplasia have a four-fold higher risk of breast cancer. We evaluated the performance of the Tyrer-Cuzick model, which was designed to predict 10-year risk of breast cancer development, in a well-defined cohort of women with atypia. PATIENTS AND METHODS: The Mayo Benign Breast Disease cohort includes 9,376 women who had a benign breast biopsy between 1967 and 1991. Among those, 331 women with atypia were identified by our study pathologists. Risk factor data for the Tyrer-Cuzick model were collated for each woman and used to predict individual risk of developing invasive breast cancer within 10 years. RESULTS: Over a median follow-up of 14.6 years, 64 (19%) of the 331 women developed invasive breast cancer. In the first 10 years after biopsy, 31 women developed invasive breast cancer whereas the Tyrer-Cuzick model predicted 58.9. The observed-to-predicted ratio was 0.53 (95% CI, 0.37 to 0.75). The concordance statistic was 0.540, revealing that the Tyrer-Cuzick model did not accurately distinguish, on an individual level, between women who developed invasive breast cancer and those who did not. CONCLUSION: The Tyrer-Cuzick model significantly overestimated risk of breast cancer for women with atypia, and individual risk estimates showed poor concordance between predicted risk and invasive breast cancer development. Thus, we cannot recommend the use of the Tyrer-Cuzick model to predict 10-year breast cancer risk in women with atypical hyperplasia.
PURPOSE: Accurate breast cancer risk assessment is vital to personalize screening and risk reduction strategies. Women with atypical hyperplasia have a four-fold higher risk of breast cancer. We evaluated the performance of the Tyrer-Cuzick model, which was designed to predict 10-year risk of breast cancer development, in a well-defined cohort of women with atypia. PATIENTS AND METHODS: The Mayo Benign Breast Disease cohort includes 9,376 women who had a benign breast biopsy between 1967 and 1991. Among those, 331 women with atypia were identified by our study pathologists. Risk factor data for the Tyrer-Cuzick model were collated for each woman and used to predict individual risk of developing invasive breast cancer within 10 years. RESULTS: Over a median follow-up of 14.6 years, 64 (19%) of the 331 women developed invasive breast cancer. In the first 10 years after biopsy, 31 women developed invasive breast cancer whereas the Tyrer-Cuzick model predicted 58.9. The observed-to-predicted ratio was 0.53 (95% CI, 0.37 to 0.75). The concordance statistic was 0.540, revealing that the Tyrer-Cuzick model did not accurately distinguish, on an individual level, between women who developed invasive breast cancer and those who did not. CONCLUSION: The Tyrer-Cuzick model significantly overestimated risk of breast cancer for women with atypia, and individual risk estimates showed poor concordance between predicted risk and invasive breast cancer development. Thus, we cannot recommend the use of the Tyrer-Cuzick model to predict 10-year breast cancer risk in women with atypical hyperplasia.
Authors: M H Gail; L A Brinton; D P Byar; D K Corle; S B Green; C Schairer; J J Mulvihill Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506
Authors: Marta Santisteban; Carol Reynolds; Emily G Barr Fritcher; Marlene H Frost; Robert A Vierkant; Stephanie S Anderson; Amy C Degnim; Daniel W Visscher; V Shane Pankratz; Lynn C Hartmann Journal: Breast Cancer Res Treat Date: 2009-09-23 Impact factor: 4.872
Authors: A C Antoniou; P D P Pharoah; G McMullan; N E Day; M R Stratton; J Peto; B J Ponder; D F Easton Journal: Br J Cancer Date: 2002-01-07 Impact factor: 7.640
Authors: W D Dupont; F F Parl; W H Hartmann; L A Brinton; A C Winfield; J A Worrell; P A Schuyler; W D Plummer Journal: Cancer Date: 1993-02-15 Impact factor: 6.860
Authors: Amy C Degnim; William D Dupont; Derek C Radisky; Robert A Vierkant; Ryan D Frank; Marlene H Frost; Stacey J Winham; Melinda E Sanders; Jeffrey R Smith; David L Page; Tanya L Hoskin; Celine M Vachon; Karthik Ghosh; Tina J Hieken; Lori A Denison; Jodi M Carter; Lynn C Hartmann; Daniel W Visscher Journal: Cancer Date: 2016-06-28 Impact factor: 6.860
Authors: Monica G Valero; Emily C Zabor; Anna Park; Elizabeth Gilbert; Ashely Newman; Tari A King; Melissa L Pilewskie Journal: Ann Surg Oncol Date: 2019-09-26 Impact factor: 5.344
Authors: Zexian Zeng; Andy Vo; Xiaoyu Li; Ali Shidfar; Paulette Saldana; Luis Blanco; Xiaoling Xuei; Yuan Luo; Seema A Khan; Susan E Clare Journal: NPJ Breast Cancer Date: 2020-06-12
Authors: Savitri Krishnamurthy; Therese Bevers; Henry M Kuerer; Benjamin Smith; Wei Tse Yang Journal: AJR Am J Roentgenol Date: 2016-12-08 Impact factor: 3.959
Authors: V Shane Pankratz; Amy C Degnim; Ryan D Frank; Marlene H Frost; Daniel W Visscher; Robert A Vierkant; Tina J Hieken; Karthik Ghosh; Yaman Tarabishy; Celine M Vachon; Derek C Radisky; Lynn C Hartmann Journal: J Clin Oncol Date: 2015-01-26 Impact factor: 44.544
Authors: Jeffrey A Tice; Diana L Miglioretti; Chin-Shang Li; Celine M Vachon; Charlotte C Gard; Karla Kerlikowske Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544